Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages e10-e12 , July 2008

The Pharmacogenetics of Morphine-Induced Analgesia: A Case Report

References 

  1. Expert Working Group of the Research Network of the European Association for the Palliative Care . Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–593
  2. Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006;14:56–64
  3. Stamer UM, Stüber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother. 2007;8:2235–2245
  4. Befort K, Filliol D, Decaillot FM, et al. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signalling. J Biol Chem. 2001;276:3130–3137
  5. de Wildt SN, Kearns GL, Leeder JS, van der Anker JN. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999;36:439–452
  6. Holthe M, Rakvag TN, Klepstad P, et al. Sequence variation in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 2003;3:17–26
  7. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000;92:1392–1399
  8. Brinkmann U, Roots I, Eichelmann M. Pharmacogenetics of the human drug-transporter gene MDR-1: impact of polymorphisms on pharmacotherapy. Drug Discov Today. 2001;6:835–839
  9. Mercadante S, Fulfaro F, Casaccio A, Barresi L. Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manage. 1999;18:347–352
  10. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25–30
  11. Hirota T, Ieiri I, Tarane H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos. 2003;31:677–680
  12. Duguay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther. 2004;75:223–233
  13. Wang D, Johnson AD, Papp AC, et al. Mulitdrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15:693–704
  14. Breda M, Bianchi M, Ripamonti C, et al. Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration. Int J Clin Pharm Res. 1991;12:93–97
  15. Gourlay GK. Advances in opioid pharmacology. Support Care Cancer. 2005;13:153–159
  16. Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics. Clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:983–1013

PII: S0885-3924(08)00211-X

doi: 10.1016/j.jpainsymman.2008.02.002

Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages e10-e12 , July 2008

Article Tools